Daily Roundup

CSL.ASX ING.ASX DNL.ASX BXN.ASX AI1.ASX

CSL Ltd Provides Update on Growth Initiatives and Transformation

CSL Limited has provided an update on its FY26 outlook, including revised revenue and NPATA guidance, as well as announcing additional pre-tax asset impairments. The company's interim CEO, Gordon Naylor, says the growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.

CSL now expects FY26 revenue to be around $15.2 billion and NPATA (excluding restructuring costs and impairments) to be around $3.1 billion, both on a constant currency basis. The key changes are related to U.S. Immunoglobulin, Albumin in China, and other factors.

The company continues to expect revenue growth in the second half of FY26 for CSL Behring, supported by underlying demand, ongoing commercial execution, and benefits from operational and transformation initiatives. CSL also expects to recognise approximately $5 billion of non-cash, pre-tax impairments across FY26 and FY27, primarily related to CSL Vifor intangible assets and under-utilised property, plant and equipment.

The global search for the next CEO is progressing, and Gordon Naylor will remain on the CSL Board as a Non-executive Director following the appointment and transition of the new CEO. Additionally, Andy Schmeltz, Chief Commercial Officer, has decided to retire, and Diego Sacristan will assume the role effective July 1, 2026.

Inghams Group Outlines Investor Day and Trading Update

Inghams Group Ltd is hosting an Investor Day presentation on May 11, 2026, providing an overview of its strategy to stabilise the business, optimise the asset, and grow the value. The company highlights that the poultry industry remains an attractive category, but Inghams' past returns have not reflected the quality of its asset base.

To address this, Inghams is shifting its focus from a volume-led to a value-led approach, aiming to maximise value per bird and drive sustainable earnings and growth. Key elements of the strategy include winning with customers through freshness, reliability, and consumer-led innovation, unlocking trapped value in operations through standardisation and planning discipline, and leveraging New Zealand as a strategic market.

Inghams expects to deliver over $130 million in EBITDA uplift from operational improvements and planning discipline over the next 3 years. The company is focused on stabilising the business, optimising the asset, and growing the value through improved execution, customer partnerships, and innovation.

Dyno Nobel Delivers Strong 1H26 Results

Dyno Nobel Limited (DNL) reported strong 1H26 results, highlighting the resilience of its explosives business. The company's underlying EBIT grew by 28% year-on-year, driven by customer wins in core and growth markets, as well as strong manufacturing performance capitalizing on tightening markets.

DNL is on track to deliver its FY28 EBIT ambition of $600 million, with a FY26 exit run rate of 65%-75%. The company also announced the signing of a binding agreement for the divestment of its Phosphate Hill business.

Dyno Nobel reaffirmed its FY26 earnings guidance, with Explosives EBIT expected to be in the range of $460 million to $500 million. Key drivers include continued customer wins, transformation benefits, and mitigation of temporary headwinds from foreign exchange, geopolitical conflicts, and supply disruptions.

Bioxyne Expands LATAM Footprint with First Supply Agreement in Costa Rica

Bioxyne Ltd, through its wholly owned subsidiary Breathe Life Sciences (BLS), has executed an expanded supply agreement with Remidose LATAM SRL to include the supply of three Dr Watson® cannabis flower SKUs to Costa Rica. This agreement represents the first international supply of medicinal cannabis flower into Costa Rica's regulated market.

The initial shipment is expected to exceed $500,000 prior to 30 June 2026, and the company expects repeat orders, subject to market conditions and regulatory approvals. This expansion establishes early Dr Watson® brand positioning and creates a regulatory and distribution foothold intended to support broader expansion across LATAM.

Adisyn Subsidiary 2D Radar to Co-Develop Radar Absorbing Drone Components

Adisyn's subsidiary, 2D Radar Absorbers Ltd, has signed an MOU with Raval, one of Israel's largest plastics groups, to co-develop graphene-enhanced injection-moulded parts for radar absorption in drones and unmanned aerial vehicles (UAVs). The collaboration combines 2D Radar's graphene-based stealth materials platform with Raval's industrial scale, automotive-grade quality systems and serial production capabilities.

This integrated stealth materials platform from underlying science through to industrial-scale production positions Adisyn to engage with defence and UAV customers, as time-to-field is increasingly mission-critical for these customers.